Regeneron Receives Another CRL for Eylea 8 mg
Regeneron faces another FDA setback for Eylea HD due to manufacturing issues.
The US Food and Drug Administration (FDA) issued a complete response letter (CRL) for the prefilled syringe option of high-dose (HD) Eylea (aflibercept) 8 mg, citing unresolved issues at Novo Nordisk's Bloomington, Indiana, plant.
- The FDA cited manufacturing issues as the reason for the CRL.
- Regeneron's manufacturing partner, Novo Nordisk, had quality control lapses, including a "pest" found on the manufacturing line in November 2024.
- The FDA tagged Novo's Indiana facility with an official action indicated (OAI) label.
Regeneron plans to improve production with new facilities.
No comment from Regeneron.
Author's summary: Regeneron faces FDA setback for Eylea HD.
More News
- Helex secures $3.5m funding to advance kidney disease therapies
- When self-censorship blocks a group's creativity, and how to get out of it?
- Who’s afraid of guitars?
- Nonfactor Therapies for Hemophilia: Current Evidence, Clinical Relevance and Cost Considerations | Managed Healthcare Executive
- 'The need for hospices is becoming ever more vital'
- Sharks Locker Room: Best 2-Week Stretch of Hockey in Years?
- NYT Mini crossword answers, hints for October 31, 2025